News

Amyris & Genome Compiler Partner to Commercialize DNA Construction Software Services for the Pharma and Biotech Industries

Combination of Amyris’s DNA construction capabilities and Genome Compiler’s computer-aided DNA design software aims to accelerate development of therapeutics

 

EMERYVILLE and LOS ALTOS, Calif., March 3, 2015 — Amyris, Inc. (Nasdaq:AMRS), an industrial bioscience company, and Genome Compiler Corp., a synthetic biology platform company, have entered into a collaboration agreement…

Cloning Like a Wizard

Construct your vector by restriction ligation in just 4 easy steps!

We’ve heard your requests, and have created a cloning wizard to put a little magic in your design!

Benefits

Error free – save time by eliminating errors from your design
Auto generate your cloned product – smart filtering of compatible restriction sites
Easily see and verify your final product befor…

Cellectis Plant Sciences and the Two Blades Foundations Announced a Cross-License Agreement

Cellectis plant sciences and the Two Blades Foundations (2Blades), two organizations with a common mission of developing techniques to improve the quality of crops, have announced a cross-license agreement of their TAL nuclease technologies. TALEN Technology™ (Cellectis plant sciences) and TAL code technology (2Blades) allow for precise genome editing in plants by utilizing nucleases. Nucleases…

Bio-Incubator Launched at Indian Insititute of Technology-Madras

Synthetic biology is ready to start flapping its wings in southern India. The Indian Institute of Technology Madras (IIT-M) located in Chennai has launched a bio-incubator assisted with 120 Million USD of funding from the Biotechnology Industry Research Assistance Council (BIRAC), a body of the central government. In an effort to promote entrepreneurship in India, the central government has…

Gen9 to Award One Million Base Pairs in G-Prize Competition

The DNA synthesis company Gen9 will be giving away one million DNA base pairs in their 2014 G-Prize competition. The competition, exclusively sponsored by Gen9, was started in 2012 as a way to support innovation in the design of synthetic DNA. Unlike in previous years, this year’s competition will be open not only to academic and nonprofit scientists, but to pre-commercial startups as well. T…

What is the European Commission Thinking?

Last week the newly appointed President of the European Commission (EC), Jean-Claude Juncker, decided to not reappoint Anne Glover to Chief Scientific Advisor to the EC and trash the position all together. Critics of Glover did not like how she gave advice to the EC; using facts instead of telling people what they wanted to hear or what was politically popular.

This position was created in…

Genome Compiler – The Platform for Synthetic Biology Tools Welcomes DNA2.0 as a Premium Synthesis Partner

Los Altos, CA and Menlo Park, CA (November 14, 2014). Genome Compiler Corp., a Los Altos based synthetic biology software company entered into a collaborative agreement with DNA2.0, a leading provider of gene synthesis and bioengineering solutions located in Menlo Park, CA. Genome Compiler will be integrating DNA2.0’s gene synthesis services into their design platform, enabling users to design…

DARPA’s New Biotech Funding Program

The Defense Advanced Research Projects Agency (DARPA) has created a simplified grant application process in order to help biotech startups skip the red tape around government grants. DARPA is offering up to $700,000 in seedling funding to businesses operating at the intersection of biology and technology, who would otherwise not pursue government grants due to the long and complicated application…

Bill & Melinda Gates Foundation Helps Launch Vaccine Development Firm

A new vaccine development firm, Affinivax, was recently initiated thanks to funding from the Bill & Melinda Gates Foundation and may receive future funding based on its performance. Affinivax plans on continuing to develop its Multiple Antigen Presenting System (MAPS) and other vaccine development projects with the initial four million dollar investment.

The company will focus on…

De Novo DNA is Joining Genome Compiler’s Suite of Advanced Tools to create Comprehensive Synthetic Biology Solutions

Los Altos, CA and City State, Pennsylvania (September 3, 2014). Genome Compiler Corp., a Los Altos based synthetic biology software company entered into a collaborative agreement with De Novo DNA, a biophysics based genetic software company located in State College, PA. Genome Compiler will be leveraging De Novo DNA’s expertise to further enrich their platform to create a more comprehensiv…

Copyright © Genome Compiler 2014. All Rights Reserved.